Deamidated gliadin peptide ELISA

Detection of gliadin antibodies has been used for a long time in celiac disease diagnostics, but suffered from a low specificity.
This disadvantage was overcome by the introduction of deamidated gliadin peptides as antigen. The ratio behind is that tissue transglutaminase catalyzes gliadin deamidation in the intestinal mucosa of celiac disease patients, resulting in deamidated gliadin peptides which are recognized by HLA receptors of immune cells. Therefore deamidated gliadin antibodies are specific for celiac disease.

Our ELISAs for detection of deamidated gliadin antibodies (E019/E020) use DGPx1 as antigen.
DGPx1 (G007) is our novel deamidated gliadin peptide, fused to a carrier protein and produced by recombinant techniques intended for usage as antigen in deamidated gliadin antibody detection.

Deamidated gliadin peptide DGPx1

  • recombinantly produced and highly purified
  • efficient coating under standard conditions
  • high diagnostic specificity
  • license free

Art. No.
E019 ZediXclusive DGPx1-ab ELISA (IgA)
ELISA for the determination of autoantibodies (IgA) against deamidated gliadin peptide
1 Kit
520 €
E020 ZediXclusive DGPx1-ab ELISA (IgG)
ELISA for the determination of autoantibodies (IgG) against deamidated gliadin peptide
1 Kit
520 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation




    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland